Richard Herrmann

Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

Volker Diehl, Jeremy Franklin, Michael Pfreundschuh et al. · New England Journal of Medicine · 2003 · 833 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

David Cunningham, Ian Chau, Deborah Stocken et al. · Journal of Clinical Oncology · 2009 · 818 citations · Full text

Medicine, Oncology, Pharmacology +12

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2002 · 657 citations · Full text

Medicine, Hematology, Molecular Genetics +14

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Richard Herrmann, G. Bodoky, Thomas Ruhstaller et al. · Journal of Clinical Oncology · 2007 · 591 citations

Medicine, Oncology, Pharmacology +15